Key result
Exogenous gangliosides are hypothesized to cross the blood-brain barrier via albumin to inhibit cell proliferation.
This study proposes mechanisms for how exogenous gangliosides cross the blood-brain barrier via serum albumin and inhibit cell proliferation by targeting DNA polymerases alpha and beta.
Hypothesis-generating for ganglioside therapies in brain tumors; leaves open clinical translation from animal models.
Gangliosides have been used to treat specific central nervous system lesions and to inhibit proliferation of neuroblastoma cells in vitro. However, the mechanisms by which they (1) cross the blood-brain barrier and (2) inhibit cell proliferation have not been clearly defined. Evidence is presented in support of the hypotheses that (1) serum albumin functions in the transport of gangliosides across the blood-brain barrier, and (2) when gangliosides inhibit cell proliferation, they do so by inhibiting the activity of DNA polymerases alpha and beta.
No takes yet. Share an insight, caveat, or question.
Schengrund et al. (1998) conducted a review in Central nervous system lesions and neuroblastoma. Exogenous Gangliosides was evaluated on Mechanisms of blood-brain barrier transport and cell proliferation inhibition. Exogenous gangliosides are hypothesized to cross the blood-brain barrier via serum albumin transport and inhibit cell proliferation by inhibiting DNA polymerases alpha and beta.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: